<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Van der Auwera,P.</style></author><author><style face="normal" font="default" size="100%">Godard,C.</style></author><author><style face="normal" font="default" size="100%">Denis,C.</style></author><author><style face="normal" font="default" size="100%">De Maeyer,S.</style></author><author><style face="normal" font="default" size="100%">R. Vanhoof</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">In vitro activities of new antimicrobial agents against multiresistant Staphylococcus aureus isolated from septicemic patients during a Belgian national survey from 1983 to 198536634</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob.Agents Chemother.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">0</style></keyword><keyword><style  face="normal" font="default" size="100%">a</style></keyword><keyword><style  face="normal" font="default" size="100%">acid</style></keyword><keyword><style  face="normal" font="default" size="100%">Activity</style></keyword><keyword><style  face="normal" font="default" size="100%">agar</style></keyword><keyword><style  face="normal" font="default" size="100%">Agent</style></keyword><keyword><style  face="normal" font="default" size="100%">Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">ALL</style></keyword><keyword><style  face="normal" font="default" size="100%">Anti-Bacterial Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Antimicrobial</style></keyword><keyword><style  face="normal" font="default" size="100%">article</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgian</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Brussels</style></keyword><keyword><style  face="normal" font="default" size="100%">drug effects</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Resistance,Microbial</style></keyword><keyword><style  face="normal" font="default" size="100%">Fluoroquinolones</style></keyword><keyword><style  face="normal" font="default" size="100%">im</style></keyword><keyword><style  face="normal" font="default" size="100%">IS</style></keyword><keyword><style  face="normal" font="default" size="100%">journal</style></keyword><keyword><style  face="normal" font="default" size="100%">Microbial Sensitivity Tests</style></keyword><keyword><style  face="normal" font="default" size="100%">microbiology</style></keyword><keyword><style  face="normal" font="default" size="100%">mupirocin</style></keyword><keyword><style  face="normal" font="default" size="100%">national</style></keyword><keyword><style  face="normal" font="default" size="100%">National Survey</style></keyword><keyword><style  face="normal" font="default" size="100%">Oxacillin</style></keyword><keyword><style  face="normal" font="default" size="100%">Patient</style></keyword><keyword><style  face="normal" font="default" size="100%">patients</style></keyword><keyword><style  face="normal" font="default" size="100%">Pefloxacin</style></keyword><keyword><style  face="normal" font="default" size="100%">Penicillin Resistance</style></keyword><keyword><style  face="normal" font="default" size="100%">pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">Print</style></keyword><keyword><style  face="normal" font="default" size="100%">Research</style></keyword><keyword><style  face="normal" font="default" size="100%">Research Support</style></keyword><keyword><style  face="normal" font="default" size="100%">SB - IM</style></keyword><keyword><style  face="normal" font="default" size="100%">Sepsis</style></keyword><keyword><style  face="normal" font="default" size="100%">Staphylococcal Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">staphylococcus</style></keyword><keyword><style  face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style  face="normal" font="default" size="100%">survey</style></keyword><keyword><style  face="normal" font="default" size="100%">Vancomycin</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">1990</style></year><pub-dates><date><style  face="normal" font="default" size="100%">0/11/1990</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">2262</style></number><volume><style face="normal" font="default" size="100%">34</style></volume><pages><style face="normal" font="default" size="100%">2260 - 2262</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The antimicrobial agents most active against bacteremic isolates of oxacillin-resistant Staphylococcus aureus isolated from 1983 to 1985 were new fluoroquinolones, including PD 117,596 and PD 127,391 (MIC for 90% of isolates [MIC90] in agar, in micrograms per milliliter, 0.1) and temafloxacin, pefloxacin, and ofloxacin (MIC90, 0.4). Other active antimicrobial agents included fusidic acid (MIC90, 0.2) and fosfomycin (MIC90, 12.5). Vancomycin was active against all isolates. Mupirocin was very active (MIC90, 0.4)</style></abstract><issue><style face="normal" font="default" size="100%">11</style></issue><custom1><style face="normal" font="default" size="100%">36634</style></custom1><section><style face="normal" font="default" size="100%">2260</style></section></record></records></xml>